Imagine a fast-track testing system for medicines that works in your local doctor's office instead of just big hospitals. It allows researchers to quickly swap in and out different treatments for flu-like illnesses to see what works best. This means people can get effective medicine earlier at home, preventing them from needing a hospital bed.
Lack of evidence-based treatments for respiratory viruses in primary care leads to higher hospital admission rates and unsustainable health service loads during pandemics.
An adaptive platform trial (APT) infrastructure across 8 countries to test the safety and efficacy of antiviral treatments in community settings.
If you are a drug developer dealing with the high cost of late-stage failures — this project developed an adaptive platform trial that tests 4 candidate treatments in primary care. This allows you to identify safety and efficacy early in the disease trajectory before moving to expensive larger phases.
If you are a diagnostics company dealing with low adoption of rapid tests — this project developed a workflow where rapid point-of-care tests are used for patient inclusion. This integrates your hardware directly into the clinical trial process for virus-specific agents.
If you are a clinic operator dealing with unsustainable patient loads during epidemics — this project developed a primary care research network. This enables your facilities to provide evidence-based therapeutics that reduce the need for hospital admissions.
Based on available project data, there is no specific pricing or cost mentioned for the use of the platform.
Yes, the project is designed for COVID-19 and COVID-like illnesses, specifically mentioning influenza and respiratory syncytial virus.
Based on available project data, the IP and licensing terms for the 4 candidate treatments are not specified.
The project period runs from 2021-12-01 to 2026-11-30, with the first phase focusing on organizational, legal, and ethical setup.
It completes the Ecraid vision by adding primary care trials to the existing suite of intensive care and hospital ward trials.
The consortium consists of 6 partners from 5 countries (BE, FR, NL, NO, UK). It is heavily weighted toward non-industrial actors, with 3 universities and 2 research organizations, and only 1 SME. There are 0 traditional industry partners, indicating the project is currently driven by academic and public health research rather than commercial interests.
Contact STICHTING EUROPEAN CLINICAL RESEARCH ALLIANCE ON INFECTIOUS DISEASES in the Netherlands
Contact us to identify potential antiviral candidates for the ECRAID-Prime platform.
